Financials in USD. Standardized financial statements.
A compact view of how Mainz Biomed B.V. turns revenue into operating income and net income.
| Metric | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 |
|---|---|---|---|---|---|---|---|
| Revenue? | $537,080 | $893,991 | $895,479 | $529,877 | $577,348 | $493,565 | $281,393 |
| Revenue Growth? | -39.9% | -0.2% | +69.0% | -8.2% | +17.0% | +75.4% | 0.0% |
| Cost of Revenue? | $763,008 | $319,108 | $385,820 | $347,726 | $399,726 | $370,480 | $342,664 |
| Gross Profit? | -$225,928 | $574,883 | $509,659 | $182,151 | $177,622 | $123,085 | -$61,271 |
| Gross Margin? | -42.1% | +64.3% | +56.9% | +34.4% | +30.8% | +24.9% | -21.8% |
| Operating Expenses? | $13.27M | $19.27M | $27.15M | $26.36M | $9.56M | $796,800 | $690,212 |
| Operating Income? | -$13.50M | -$18.70M | -$26.64M | -$26.44M | -$9.72M | -$766,090 | -$921,909 |
| EBITDA? | -$12.88M | -$19.56M | -$25.01M | -$25.72M | -$11.28M | -$257,641 | -$702,077 |
| Income Before Tax | -$16.21M | -$21.65M | -$26.30M | -$26.39M | -$11.70M | -$586,895 | -$957,055 |
| Income Tax Expense | $0 | $0 | $0 | $0 | $377,122 | $0 | $0 |
| Net Income? | -$16.21M | -$21.65M | -$26.30M | -$26.45M | -$11.69M | -$586,895 | -$957,055 |
| EPS? | $-2.70 | $-22.36 | $-1.62 | $-1.87 | $-1.67 | $-0.05 | $-0.10 |
| Diluted EPS? | $-2.70 | $-22.36 | $-1.62 | $-1.87 | $-1.67 | $-0.05 | $-0.10 |
Revenue, profitability, margins, EPS, and share-count trends over time.
Top-line demand and scale over time
Profit left after direct production costs
Core business profitability before financing and tax
Bottom-line profit after all expenses
Profit allocated to each diluted share
Share count trend that affects EPS quality
Gross, operating, and net margin quality